var title_f14_47_15088="Urine in AIP";
var content_f14_47_15088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine in acute intermittent porphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 455px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of urine from a normal subject (left) and a subject with acute intermittent porphyria (middle). The colors are compared with a dilute aqueous solution of red wine (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Shigeru Sassa, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15088=[""].join("\n");
var outline_f14_47_15088=null;
var title_f14_47_15089="Right sided pressures";
var content_f14_47_15089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal right-sided pressure tracings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal, simultaneously recorded pressures from the right atrium (RA) and right ventricle (RV). The RA pressure tracing shows a normal pattern of a, c, and v waves and there is no gradient during diastole. The RV systolic and diastolic pressures are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kern MJ (Ed), Cardiac catheterization Handbook, 2nd ed, Mosby-Year Book, Inc., St. Louis, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15089=[""].join("\n");
var outline_f14_47_15089=null;
var title_f14_47_15090="Bronchoscopy brush";
var content_f14_47_15090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchoscopy brush",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A cytology/microbiology brush is shown, extending from its sheath.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15090=[""].join("\n");
var outline_f14_47_15090=null;
var title_f14_47_15091="Patient information: Preparing for pregnancy when you have diabetes (The Basics)";
var content_f14_47_15091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/62/31714\">",
"         Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36483\">",
"         Patient information: Diabetes and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/34/11810\">",
"         Patient information: Diabetic retinopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?10/45/10966\">",
"         Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/26/36259\">",
"         Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/22/9572\">",
"         Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/20/3397\">",
"         Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/32/31239\">",
"         Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preparing-for-pregnancy-when-you-have-diabetes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H92847365\">",
"      <span class=\"h1\">",
"       How should I prepare for pregnancy if I have diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, it is very important that you talk to your doctors",
"      <strong>",
"       before",
"      </strong>",
"      you start trying to get pregnant. You will need to see an obstetrician (a doctor who takes care of pregnant women) and your primary care doctor. If you see an endocrinologist (a doctor who handles your diabetes), you should mention your pregnancy plans to him or her, too. These doctors can make sure that you do everything possible to have a healthy baby.",
"     </p>",
"     <p>",
"      Before you start trying to get pregnant, you will need to work closely with your healthcare team to get your blood sugar as close to normal as possible. That might mean using more insulin, if you already use it. Or switching to insulin, if you do not already use it. Plus, you might need to change the way you eat and increase your activity levels. &nbsp;",
"     </p>",
"     <p>",
"      Normal blood sugar levels help prevent miscarriages and birth defects.",
"     </p>",
"     <p>",
"      You should also talk to your doctors about",
"      <strong>",
"       all",
"      </strong>",
"      medicines you take&mdash;including any supplements or herbal medicines. If you use any medicines that are not safe to take during pregnancy, you might need to switch or go off them.",
"     </p>",
"     <p>",
"      This article discusses the things women with diabetes should do before getting pregnant. There are also steps that",
"      <strong>",
"       all",
"      </strong>",
"      women should take before trying to get pregnant. (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       \"Patient information: How to plan and prepare for a healthy pregnancy (The Basics)\"",
"      </a>",
"      .)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92847372\">",
"      <span class=\"h1\">",
"       Which medicines should I stop taking before I try to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should stop taking:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Certain medicines used to treat high blood pressure. It is especially important to stop medicines called ACE inhibitors and angiotensin receptor blockers (sometimes called ARBs). These medicines can cause birth defects.",
"        <br/>",
"        <br/>",
"        But don&rsquo;t stop your high blood pressure medicine on your own. High blood pressure can be harmful. Your doctor will switch you to a blood pressure medicine that is safe to take during pregnancy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines called statins, which are used to lower cholesterol. These medicines have not been well studied in pregnant women. But doctors recommend stopping them, because there is a chance they could affect a baby&rsquo;s development.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Remember, by the time a woman discovers she is pregnant, her baby has already started to form many important body parts. That&rsquo;s why it is not enough to stop taking medicines that might be harmful when you learn you are pregnant. &nbsp;",
"     </p>",
"     <p>",
"      If you get pregnant while taking any medicines, tell your doctors right away. They can explain any possible risks to your baby and help you decide how best to move forward. &nbsp;",
"     </p>",
"     <p>",
"      Before you start trying to get pregnant, your doctors will probably also want you to stop taking diabetes medicines that come in pill form, such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?15/38/15973?source=see_link\">",
"       glyburide",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=see_link\">",
"       metformin",
"      </a>",
"      . They will want you to use insulin instead.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92847379\">",
"      <span class=\"h1\">",
"       Will I need any tests before I start trying to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You will need these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         An eye exam",
"        </strong>",
"        (if you have not had one in the last 12 months) &mdash; You will need to be checked for an eye disease called &ldquo;diabetic retinopathy.&rdquo; This condition is caused by diabetes, and it can lead to vision loss or even blindness. Pregnancy can increase the chance that a woman will get diabetic retinopathy, and it can make the condition worse in women who already have it. If you have severe diabetic retinopathy, you might need to treat the condition before you get pregnant.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Blood and urine tests to check the health of your kidneys",
"        </strong>",
"        &mdash; People with diabetes are at risk for kidney disease. Pregnancy can worsen kidney disease that already exists. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Blood pressure test",
"        </strong>",
"        &mdash; Having high blood pressure during pregnancy can cause problems for you and your baby. If your blood pressure is too high, your doctors might give you medicines to treat it. But they will choose medicines that are safe to use during pregnancy. Some of the medicines normally used to treat high blood pressure are not safe to use during pregnancy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Blood tests to measure thyroid hormone levels",
"        </strong>",
"        &mdash; Having normal thyroid hormone levels is very important for a developing baby. If your tests show that your thyroid hormone levels are too high or too low, you might need treatments to get them back to normal.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Urine tests to check for infection",
"        </strong>",
"        &mdash; Women with diabetes can have bladder or kidney infections and not know it. It&rsquo;s important to treat these before pregnancy. &nbsp;",
"        <strong>",
"        </strong>",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92847431\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"       Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"       Patient information: Diabetes and diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=see_link\">",
"       Patient information: Diabetic retinopathy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"       Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/20/3397?source=see_link\">",
"       Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=see_link\">",
"       Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/47/15091?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16417 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15091=[""].join("\n");
var outline_f14_47_15091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92847365\">",
"      How should I prepare for pregnancy if I have diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92847372\">",
"      Which medicines should I stop taking before I try to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92847379\">",
"      Will I need any tests before I start trying to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92847431\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=related_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=related_link\">",
"      Patient information: Diabetic retinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/20/3397?source=related_link\">",
"      Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=related_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_47_15092="Cutaneous anthrax";
var content_f14_47_15092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Cutaneous anthrax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Necrotic wound with a hemorrhagic rim on the left hand of a patient with cutaneous anthrax.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cinquetti G, Banal F, Dupuy A-L, et al. Three related cases of cutaneous anthrax in France. Medicine 2009; 88:371. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15092=[""].join("\n");
var outline_f14_47_15092=null;
var title_f14_47_15093="Male perineum muscles";
var content_f14_47_15093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Muscles of the male perineum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the muscles and fascia of the male perineum. Note the anococcygeal raphe, the levator ani (iliococcygeus) muscles, the deep and superficial transverse perineal muscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15093=[""].join("\n");
var outline_f14_47_15093=null;
var title_f14_47_15094="Sufentanil: Drug information";
var content_f14_47_15094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sufentanil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/45/44755?source=see_link\">",
"    see \"Sufentanil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/6/96?source=see_link\">",
"    see \"Sufentanil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sufenta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sufentanil Citrate Injection, USP;",
"     </li>",
"     <li>",
"      Sufenta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Anilidopiperidine Opioid;",
"     </li>",
"     <li>",
"      General Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose should be based on body weight. In obese patients (ie, &gt;20% above ideal body weight), use lean body weight to determine dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgical analgesia (surgery duration: 1-2 hours):",
"     </b>",
"     I.V.: 1-2 mcg/kg with N",
"     <sub>",
"      2",
"     </sub>",
"     O/O",
"     <sub>",
"      2",
"     </sub>",
"     ; maintenance: 5-20 mcg as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesia:",
"     </b>",
"     Epidural: 10-15 mcg with 10 mL bupivacaine 0.125% with/without epinephrine. May repeat at &ge;1-hour interval for 2 additional doses.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F223621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/6/96?source=see_link\">",
"      see \"Sufentanil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     I.V.: Children 2-12 years: Induction: 10-25 mcg/kg (10-15 mcg/kg most common dose) with 100% O",
"     <sub>",
"      2",
"     </sub>",
"     ; maintenance: up to 1-2 mcg/kg total dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 50 mcg/mL (1 mL, 2 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sufenta&reg;: 50 mcg/mL (1 mL, 2 mL, 5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F223637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F223642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, atropine, bivalirudin, cefepime, ceftriaxone, cisatracurium, dexamethasone sodium phosphate, dexmedetomidine, diazepam, diphenhydramine, etomidate, fenoldopam, haloperidol, hetastarch in lactate electrolyte injection (Hextend&reg;), hydroxyzine, ketorolac, linezolid, methotrimeprazine, metoclopramide, midazolam, palonosetron, phenobarbital, prochlorperazine edisylate, propofol, remifentanil, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Lorazepam, phenytoin, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atracurium, atropine, bupivacaine, dexamethasone sodium phosphate, diphenhydramine, haloperidol, hydroxyzine, ketorolac, methotrimeprazine, metoclopramide, midazolam, prochlorperazine edisylate, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, lorazepam, phenobarbital, phenytoin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesic supplement in maintenance of general anesthesia; epidural analgesic in conjunction with a local anesthetic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SUFentanil may be confused with alfentanil, fentaNYL",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sufenta&reg; may be confused with Alfenta&reg;, Sudafed&reg;, Survanta&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Pruritus (epidural: 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (dose related; 3% to 9%), hyper-/hypotension (3% to 9%; more common with I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (3% to 9%), CNS depression, confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 9%), vomiting (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chest wall rigidity (dose related; 3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, apnea, arrhythmia, biliary spasm, bronchospasm, cardiac arrest, chills, circulatory depression; cold, clammy skin; dizziness, dysesthesia, erythema, itching, laryngospasm, mental depression, paradoxical CNS excitation or delirium, physical and psychological dependence with prolonged use, respiratory depression (dose related), seizure, skeletal muscle rigidity, skin rash, tachycardia, urinary retention, urinary tract spasm, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sufentanil or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opioid agonist toxicities: Shares the toxic potentials of opiate agonists, and precautions of opiate agonist therapy should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: Use with caution when administering to patients with bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese. Consider use of lean body weight for dosing in patients &gt;20% over ideal body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid infusion: Inject slowly over 3-5 minutes; rapid I.V. infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest; nondepolarizing skeletal muscle relaxant may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained individuals: Due to the high incidence of apnea, hypotension, tachycardia and muscle rigidity; it should be administered by individuals specifically trained in the use of anesthetic agents and should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia setting; resuscitative and intubation equipment should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatric use: Use caution in neonates as clearance of sufentanil is much slower than adults; neonates with cardiovascular disease have an even slower clearance.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F223631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Anilidopiperidine Opioids may enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Anilidopiperidine Opioids may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Anilidopiperidine Opioids may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.  Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5050046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies suggest embryocidal effects when given I.V. for a period of 10 days to &gt;30 days. No evidence of teratogenic effects observed in animals. Administration of epidural sufenanil with bupivacaine with or without epinephrine is indicated in labor and delivery. Intravenous use or larger epidural doses are not recommended in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sufenta Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/mL (1 mL): $5.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/2 mL (2 mL): $9.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg/5 mL (5 mL): $19.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (SUFentanil Citrate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/mL (1 mL): $3.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/2 mL (2 mL): $5.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg/5 mL (5 mL): $13.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5050707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory and mental status, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F223600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fastfen (BR);",
"     </li>",
"     <li>",
"      Fentafienil (IT);",
"     </li>",
"     <li>",
"      Sufenta (AR, AT, BE, CH, CN, CZ, DE, DK, FI, FR, HR, ID, LU, NL, NO, PL, PT, SE, TR, TW, UY, ZA);",
"     </li>",
"     <li>",
"      Sufenta Forte (ZA);",
"     </li>",
"     <li>",
"      Sufentil (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opioid receptors throughout the CNS. Once receptor binding occurs, effects are exerted by opening K+ channels and inhibiting Ca++ channels. These mechanisms increase pain threshold, alter pain perception, inhibit ascending pain pathways; short-acting narcotic; dose-related inhibition of catecholamine release (up to 30 mcg/kg) controls sympathetic response to surgical stress.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Analgesia: I.V.: 1-3 minutes; epidural: 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Dose dependent; Epidural:10-15 mcg with bupivacaine: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Neonates: 79%; Adults: 91% to 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic and small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Neonates: 5-10 hours; Infants &amp; Children: 55-139 minutes; Adults: 164 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine as metabolites (2% excreted as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bovill JG, Sebel PS, Blackburn CL, et al, &ldquo;The Pharmacokinetics of Sufentanil in Surgical Patients,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1984, 61(5):502-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15094/abstract-text/6238552/pubmed\" id=\"6238552\" target=\"_blank\">",
"        6238552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bowdle TA, &ldquo;Myoclonus Following Sufentanil Without EEG Seizure Activity,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1987, 67(4):593-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15094/abstract-text/2959172/pubmed\" id=\"2959172\" target=\"_blank\">",
"        2959172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay J, Gaudreault P, Tang A, et al, &ldquo;Pharmacokinetics of Sufentanil in Normal Children,&rdquo;",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 1992, 39(1):14-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15094/abstract-text/1531117/pubmed\" id=\"1531117\" target=\"_blank\">",
"        1531117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gust R and B&ouml;hrer H, &ldquo;Stiff-Man Syndrome Associated With Continuous Sufentanil Administration,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1995, 50(6):575.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15094/abstract-text/7618699/pubmed\" id=\"7618699\" target=\"_blank\">",
"        7618699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15094/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosow CE, &ldquo;Sufentanil Citrate: A New Opioid Analgesic for Use in Anaesthesia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1984, 4(1):11-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15094/abstract-text/6230606/pubmed\" id=\"6230606\" target=\"_blank\">",
"        6230606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scholz J, Steinfath M, and Schulz M, &ldquo;Clinical Pharmacokinetics of Alfentanil, Fentanyl, and Sufentanil. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1996, 31(4):275-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15094/abstract-text/8896944/pubmed\" id=\"8896944\" target=\"_blank\">",
"        8896944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seguin JH, Erenberg A, and Leff RD, &ldquo;Safety and Efficacy of Sufentanil Therapy in the Ventilated Infant,&rdquo;",
"      <i>",
"       Neonatal Netw",
"      </i>",
"      , 1994, 13(4):37-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, Trusley C, Ben M, et al, &ldquo;Physical And Chemical Stability of Palonsetron Hydrochloride With Five Opiate Agonists During Simulated Y-Site Administration,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2007, 64 (11):1209-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15094/abstract-text/17519464/pubmed\" id=\"17519464\" target=\"_blank\">",
"        17519464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9954 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-FD3AE0A3B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15094=[""].join("\n");
var outline_f14_47_15094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223606\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223607\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223635\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223609\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223621\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223610\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223591\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223577\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223637\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223642\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223592\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223644\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223633\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223597\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223581\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223631\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223586\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223587\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5050046\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323903\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5050707\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223600\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223580\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223596\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9954|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/45/44755?source=related_link\">",
"      Sufentanil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/6/96?source=related_link\">",
"      Sufentanil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_47_15095="Mercaptopurine: Pediatric drug information";
var content_f14_47_15095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mercaptopurine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"    see \"Mercaptopurine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/4/30789?source=see_link\">",
"    see \"Mercaptopurine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Purinethol&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Purinethol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Purine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"      see \"Mercaptopurine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL):",
"     </b>",
"     Refer to individual protocols.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Maintenance therapy: Oral: 1.5-2.5 mg/kg/dose once daily, combined with other agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing: Adolescents &ge;15 years: Multiple dosage regimens reported:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Consolidation phase:",
"     </i>",
"     Oral: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 0-27 days (5-week course)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 0-13 and days 28-41 (9-week course) (Stock, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Early intensification (two 4-week courses):",
"     </i>",
"     Oral: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1-14 (Larson, 1995; Larson, 1998; Stock, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Interim maintenance:",
"     </i>",
"     Oral: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 0-41 (8-week course)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1-70 (12-week course) (Larson, 1995; Larson, 1998; Stock, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Maintenance (prolonged):",
"     </i>",
"     Oral: 50 mg 3 times daily for 2 years (Kantarjian, 2000; Thomas, 2004)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 years from diagnosis (Larson, 1995; Larson, 1998; Stock, 2008)",
"     <b>",
"      or",
"     </b>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 years (girls) or 3 years (boys) from first interim maintenance (Stock, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute promyelocytic leukemia (APL):",
"     </b>",
"     Limited data available: Adolescents &ge;15 years: Oral:  60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 1 year; in combination with tretinoin and methotrexate  (Powell, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Autoimmune hepatitis:",
"     </b>",
"     Very limited data available: Oral: 1.5 mg/kg/day in combination with prednisone; not considered first-line, typically used for patient who do not tolerate azathioprine (Manns, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Inflammatory bowel disease (eg, Crohn&rsquo;s disease, ulcerative colitis):",
"     </b>",
"     Limited data available: 1-1.5 mg/kg/day (Markowitz, 2000;  Punati, 2011; Sandhu, 2010). Some data suggest that pediatric patients &le;6 years may require higher doses to achieve remission; a median dose of 1.68 mg/kg/day (maximum daily dose: 2.4 mg/kg/day) was reported to induce remission in 62% of patients vs 17% of those receiving lower doses (&lt;1.5 mg/kg/day study group; median dose: 1.18 mg/kg/day) (Grossman, 2008; Sandborn, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Acute lymphoblastic leukemia (ALL):",
"     </b>",
"     Maintenance: Oral: 1.5-2.5 mg/kg/dose once daily; also consult guidelines for details on combination regimens",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment with concurrent allopurinol:",
"     </b>",
"     Children, Adolescents, and Adults: Reduce mercaptopurine dosage to 25% to 33% of the usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in TPMT-deficiency:",
"     </b>",
"     Children, Adolescents, and Adults: Dosing not established; substantial reductions are generally required only in homozygous deficiency; however, some experts also recommend dosage reduction with intermediate activity or heterozygous phenotype (Sandborn, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Children and Adolescents: The manufacturer's labeling recommends starting with reduced doses in patients with renal impairment to avoid accumulation; however, no specific dosage adjustment is provided. The following adjustments have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Children, Adolescents, and Adults: The manufacturer&rsquo;s labeling recommends considering a reduced dose in patients with hepatic impairment; however, no specific dosage adjustment is provided.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purinethol&reg;: 50 mg [DSC] [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Preferably on an empty stomach (1 hour before or 2 hours after meals). For the treatment of ALL in children: Administration in the evening has demonstration superior outcome; administration with food did not significantly affect outcome (Schmiegelow, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment of acute lymphoblastic leukemia (ALL) in combination with other agents (eg, methotrexate) [FDA approved in pediatric patients (age not specified) and adults]; has also been used to treat inflammatory bowel disease, autoimmune hepatitis, and maintenance treatment in acute promyelocytic leukemia (APL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mercaptopurine may be confused with methotrexate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Purinethol&reg; may be confused with propylthiouracil",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       To avoid potentially serious dosage errors, the terms &ldquo;6-mercaptopurine&rdquo; or &ldquo;6-MP&rdquo; should be avoided; use of these terms has been associated with sixfold overdosages.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Azathioprine is metabolized to mercaptopurine; concurrent use of these commercially-available products has resulted in profound myelosuppression.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F193275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drug fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, hyperpigmentation, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, intestinal ulcers, mucositis/oral lesions (rare), nausea (minimal), pancreatitis, sprue-like symptoms, stomach pain, vomiting (minimal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Oligospermia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression (onset 7-10 days; nadir 14 days; recovery: 21 days); anemia, bleeding, granulocytopenia, leukopenia, marrow hypoplasia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, ascites, biliary stasis, hepatic damage/injury, hepatic encephalopathy, hepatic necrosis, hepatomegaly, intrahepatic cholestasis, jaundice, parenchymal cell necrosis, toxic hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hyperuricosuria, renal toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hepatosplenic T cell lymphoma, immunosuppression, infection, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mercaptopurine or any component; patients whose disease showed prior resistance to mercaptopurine or thioguanine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in renal impairment; consider dosage adjustment; some renal adverse effects may be minimized with hydration and prophylactic antihyperuricemic therapy. Should only be used by experienced physician.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Dose-related hematologic toxicities (leukopenia, thrombocytopenia, anemias, including macrocytic anemia or pancytopenia) may occur; however, these may also be indicative of disease progression. Hematologic toxicity may be delayed; bone marrow may appear hypoplastic (could also appear normal); monitor for bleeding (due to thrombocytopenia) or infection (due to neutropenia). Patients with intermediate TPMT activity (heterozygous) may be at risk for increased myelosuppression, although will generally tolerate normal mercaptopurine doses; those with low or absent TPMT activity (homozygous) are at risk for developing severe and life-threatening hematologic toxicity and will likely require significant dose reductions. TPMT genotyping or phenotyping may assist in identifying patients at risk for developing toxicity. Monitor hematologic function closely; may require dosage reduction or temporary discontinuation of mercaptopurine if there is a rapid decrease or persistently low leukocyte counts. Patients on concurrent therapy with drugs which may inhibit TPMT (eg, olsalazine) or xanthine oxidase (eg, allopurinol) may be at higher risk for myelosuppressive effects. Reduced dosage of mercaptopurine may be recommended when used concurrently with allopurinol. Mercaptopurine is immunosuppressive; the risk for infection is increased; common signs of infection, such as fever and leukocytosis may not occur; lethargy and confusion may be more prominent signs of infection. Because azathioprine is metabolized to mercaptopurine, concomitant use with azathioprine may result in profound myelosuppression and should be avoided. Immune response to vaccines may be diminished.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The development of secondary hemophagocytic lymphohistiocytosis (HLH), a rare and frequently fatal activation of macrophages which causes phagocytosis of all bone marrow blood cell lines, is increased (100-fold) in pediatric patients diagnosed with inflammatory bowel disease; this risk is further increased with concomitant thiopurine (ie, azathioprine or mercaptopurine) therapy, Epstein-Barr virus, or other possible infections; if patient presents with fever (at least 5 days), cervical lymphadenopathy and lymphopenia, discontinue immunosuppressive therapy and further diagnostic evaluation for HLH should be performed; diagnostic delay associated with increased mortality  (Biank, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hepatotoxicity has been reported, including jaundice, ascites, hepatic necrosis (may be fatal), intrahepatic cholestasis, parenchymal cell necrosis, and/or hepatic encephalopathy; may be due to direct hepatic cell damage or hypersensitivity. While hepatotoxicity or hepatic injury may occur at any dose, dosages &gt;2.5 mg/kg/day are associated with a higher incidence. Signs of jaundice generally appear early in treatment, after ~1-2 months (range: 1 week to 8 years) and may resolve following discontinuation; recurrence with rechallenge has been noted. Monitor liver function tests; more frequent monitoring  recommended when used in combination with other hepatotoxic drugs or in patients with pre-existing hepatic impairment. Consider a reduced dose in patients with hepatic impairment. Withhold treatment for clinical signs of jaundice (hepatomegaly, anorexia, tenderness), deterioration in liver function tests, toxic hepatitis, or biliary stasis until hepatotoxicity is ruled out.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Mutagenicity reported in humans; may cause birth defects. Immunosuppressive agents, including mercaptopurine, are associated with the development of lymphoma and other malignancies. In an analysis of T-cell lymphomas associated with TNF blockers (with or without thiopurines) for the treatment of rheumatoid arthritis, Crohn&rsquo;s disease, ulcerative colitis, or ankylosing spondylitis, an increase in the incidence of T-cell lymphomas, most commonly mycosis fungoides/Sezary syndrome and hepatosplenic T-cell lymphoma (HSTCL) was reported  (Deepak, 2013). HSTCL is a rare white blood cell cancer that is usually fatal. Most HSTCL cases occurred in patients treated with a combination of TNF blockers and thiopurines, although  cases of HSTCL also occurred in patients receiving azathioprine or mercaptopurine monotherapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     To avoid potentially serious dosage errors, the terms &ldquo;6-mercaptopurine&rdquo; or &ldquo;6-MP&rdquo; should be avoided; use of these terms has been associated with sixfold overdosages.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May decrease the metabolism of Thiopurine Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May decrease the metabolism of Mercaptopurine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Febuxostat: May increase the serum concentration of Mercaptopurine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfamethoxazole: May enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Mercaptopurine may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Mercaptopurine may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13361082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm if administered during pregnancy. Case reports of fetal loss have been noted with mercaptopurine administration during the first trimester; adverse effects have also been noted with second and third trimester use. Women of child bearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (weekly initially, although clinical status may require increased frequency), bone marrow exam (to evaluate marrow status), liver function tests (weekly initially, then monthly; monitor more frequently if on concomitant hepatotoxic agents), renal function, urinalysis; consider TPMT genotyping to identify TPMT defect (if severe toxicity occurs)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For use in inflammatory bowel disease, monitor CBC with differential weekly for 1 month, then biweekly for 1 month, followed by monitoring every 1-2 months throughout the course of therapy. LFTs should be assessed every 3 months. Monitor for signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) (Sandhu, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Purine antagonist which inhibits DNA and RNA synthesis; acts as false metabolite and is incorporated into DNA and RNA, eventually inhibiting their synthesis; specific for the S phase of the cell cycle",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Variable and incomplete (~50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     &gt; total body water; CNS penetration is negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~19%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and in GI mucosa; hepatically via xanthine oxidase and methylation via TPMT to sulfate conjugates, 6-thiouric acid, and other inactive compounds; first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 21  minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 47 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (46% as mercaptopurine and metabolites)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/4/30789?source=see_link\">",
"      see \"Mercaptopurine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take daily dose at the same time each day. Preferable to take on an empty stomach, 1 hour before or 2 hours after meals. Maintain adequate hydration unless instructed to restrict fluid intake. Susceptibility to infection may be increased. May cause nausea, vomiting, diarrhea, loss of appetite, weakness or lethargy, mouth sores, or headache. Report signs of persistent fever, opportunistic infection (eg, fever, chills, sore throat, burning urination, fatigue), bleeding (eg, tarry stools, easy bruising), unresolved mouth sores, nausea or vomiting, swelling of extremities, respiratory difficulty, unusual weight gain, signs of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss), jaundice, or changes in urinary pattern. Women with childbearing potential should avoid becoming pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F193210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 50 mg/mL oral suspension may be prepared in a vertical flow hood with tablets and a mixture of sterile water for injection (SWFI), simple syrup, and cherry syrup. Crush thirty 50 mg tablets in a mortar and reduce to a fine powder. Add ~5 mL SWFI and mix to a uniform paste; then add ~10 mL simple syrup; mix while continuing to add cherry syrup to make a final volume of 30 mL; transfer to a calibrated bottle. Label \"shake well\" and \"caution chemotherapy\". Stable for 35 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Aliabadi HM, Romanick M, Desai, S, et al, &ldquo;Effect of Buffer and Antioxidant on Stability of a Mercaptopurine Suspension,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2008, 65(5):441-7.",
"     <span class=\"pubmed-id\">",
"      18281736",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, 173.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biank VF, Sheth MK, Talano J, et al, \"Association of Crohn's disease, Thiopurines, and Primary Epstein-Barr Virus Infection With Hemophagocytic Lymphohistiocytosis,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2011, 159(5):808-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/21722918/pubmed\" id=\"21722918\" target=\"_blank\">",
"        21722918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deepak P, Sifuentes H, Sherid M, et al, &ldquo;T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-&alpha;) Inhibitors: Results of the REFURBISH Study,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2013, 108(1):99-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/23032984/pubmed\" id=\"23032984\" target=\"_blank\">",
"        23032984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardiner SJ, Gearry RB, Roberts RL, et al, &ldquo;Exposure to Thiopurine Drugs Through Breast Milk is Low Based on Metabolite Concentrations in Mother-Infant Pairs,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2006, 62(4):453-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/16995866/pubmed\" id=\"16995866\" target=\"_blank\">",
"        16995866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gremse DA and Crissinger KD, &ldquo;Ulcerative Colitis in Children: Medical Management,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(12):807-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/12431133/pubmed\" id=\"12431133\" target=\"_blank\">",
"        12431133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grossman AB, Noble AJ, Mamula P, et al, \"Increased Dosing Requirements for 6-Mercaptopurine and Azathioprine in Inflammatory Bowel Disease Patients Six Years and Younger,\"",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2008, 14(6):750-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/18266236/pubmed\" id=\"18266236\" target=\"_blank\">",
"        18266236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, O'Brien S, Smith TL, et al, &ldquo;Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(3): 547-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/10653870 /pubmed\" id=\"10653870 \" target=\"_blank\">",
"        10653870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Burns CP, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 85(8):2025-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/7718875 /pubmed\" id=\"7718875 \" target=\"_blank\">",
"        7718875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Linker CA, et al, \"A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 92(5):1556-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/9716583/pubmed\" id=\"9716583\" target=\"_blank\">",
"        9716583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manns MP, Czaja AJ, Gorham JD, et al, &ldquo;Diagnosis and Management of Autoimmune Hepatitis,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2010, 51(6):2193-213.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/20513004/pubmed\" id=\"20513004\" target=\"_blank\">",
"        20513004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markowitz J, Grancher K, Kohn N, et al, &ldquo;A Multicenter Trial of 6-Mercaptopurine and Prednisone in Children With Newly Diagnosed Crohn's Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2000, 119(4):895-902.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/11040176/pubmed\" id=\"11040176\" target=\"_blank\">",
"        11040176",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mosesso P and Palitti F, \"The Genetic Toxicology of 6-Mercaptopurine,\"",
"      <i>",
"       Mutat Res",
"      </i>",
"      , 1993, 296(3):279-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/7680107/pubmed\" id=\"7680107\" target=\"_blank\">",
"        7680107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo;",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 2011, 23(12):1150-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/21941193/pubmed\" id=\"21941193\" target=\"_blank\">",
"        21941193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell BL, Moser B, Stock W, et al, &ldquo;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(19):3751-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/20705755/pubmed\" id=\"20705755\" target=\"_blank\">",
"        20705755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Punati J, Markowitz J, Lerer T, et al, \"Effect of Early Immunomodulator Use in Moderate to Severe Pediatric Crohn Disease,\"",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2008, 14(7):949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/18306311/pubmed\" id=\"18306311\" target=\"_blank\">",
"        18306311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandborn WJ, &ldquo;A Review of Immune Modifier Therapy for Inflammatory Bowel Disease: Azathioprine, 6-mercaptopurine, Cyclosporine, and Methotrexate,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 1996, 91(3):423-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/8633486/pubmed\" id=\"8633486\" target=\"_blank\">",
"        8633486",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandhu BK, Fell JME, Beattie RM, et al, &ldquo;Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom.&rdquo;",
"      <i>",
"       JPGN",
"      </i>",
"      , 2010, 50:1-13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmiegelow K, Glomstein A, Kristinsson J, et al, &ldquo;Impact of Morning versus Evening Schedule for Oral Methotrexate and 6-Mercaptopurine on Relapse Risk for Children With Acute Lymphoblastic Leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO),&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 1997, 19(2):102-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/9149738/pubmed\" id=\"9149738\" target=\"_blank\">",
"        9149738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stock W, La M, Sanford B, et al, &ldquo;What Determines the Outcomes for Adolescents and Young Adults With Acute Lymphoblastic Leukemia Treated on Cooperative Group Protocols? A Comparison of Children's Cancer Group and Cancer and Leukemia Group B Studies,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(5):1646-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15095/abstract-text/18502832/pubmed\" id=\"18502832\" target=\"_blank\">",
"        18502832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12582 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-72FD83CAD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15095=[""].join("\n");
var outline_f14_47_15095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193227\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193228\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048478\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048470\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193204\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193188\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048482\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048473\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048481\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193278\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193275\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048469\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048468\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299673\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193197\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193199\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361082\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048477\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048467\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048485\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048475\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193210\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12582|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=related_link\">",
"      Mercaptopurine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/4/30789?source=related_link\">",
"      Mercaptopurine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_47_15096="Vancomycin dosing and serum concentration monitoring in adults";
var content_f14_47_15096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vancomycin dosing and serum concentration monitoring in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/47/15096/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/47/15096/contributors\">",
"     Richard H Drew, PharmD, MS, BCPS, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/47/15096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/47/15096/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/47/15096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/47/15096/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/47/15096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is a glycopeptide antibiotic used for treatment of patients with suspected or proven invasive gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Appropriate dosing requires consideration of the infection site, patient weight, renal function, and pathogen susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Therefore, careful attention to individualizing therapy and prudent use of serum concentration monitoring (when indicated) will assist in selecting the appropriate dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    pharmacokinetics, pharmacodynamics, dosing, use of serum concentration monitoring, and adverse effects will be reviewed here. Vancomycin hypersensitivity is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link\">",
"     \"Vancomycin hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    undergoes limited absorption when administered orally and is therefore restricted to parenteral administration for the treatment of systemic infections. It is distributed widely to various tissues and body fluids, with a volume of distribution ranging from 0.4 to 1",
"    <span class=\"nowrap\">",
"     L/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/7\">",
"     7",
"    </a>",
"    ]. Penetration of vancomycin may vary by site and concomitant disease states. For example, limited CSF penetration may be enhanced by the presence of inflamed meninges. The favorable penetration of vancomycin into skin tissues may be significantly impaired in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/8\">",
"     8",
"    </a>",
"    ]. Vancomycin penetration into lung epithelial lining fluid is limited relative to that of simultaneous serum concentration (the ratio of lung tissue to serum concentration is about 0.25) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/9\">",
"     9",
"    </a>",
"    ]. Vancomycin's primary route of elimination is via renal excretion of unchanged drug. The rate of elimination is directly related to creatinine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro and animal model studies describing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    pharmacodynamics indicate the rate of killing depends primarily upon time of concentration exceeding the organism's minimum inhibitory concentration (MIC). The area under the time concentration curve (AUC:MIC ratio) is the best predictor of efficacy in these models [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data to characterize the pharmacodynamic properties of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    against methicillin-resistant S. aureus (MRSA) in humans are limited. Some studies suggest that a ratio of area under the time concentration curve (AUC) to minimum inhibitory concentration (MIC) of &ge;400 may be desirable, although this",
"    <span class=\"nowrap\">",
"     AUC/MIC",
"    </span>",
"    target may not be reliably achieved in many patients who have serious S. aureus infections due to isolates with MIC value &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have reported relationships between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    treatment outcome and in vitro susceptibility of S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/12,15-17\">",
"     12,15-17",
"    </a>",
"    ]. Clinical failure rates in these studies were significantly higher in patients infected with isolates with MICs &ge;2",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Although these studies did not characterize vancomycin exposure in these patients, data from in vitro pharmacodynamic models suggest that suboptimal exposure of S. aureus to vancomycin may facilitate the emergence of isolates expressing intermediate or heteroresistance to glycopeptides [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the treatment of infection due MRSA isolates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    MIC &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    optimal pharmacodynamic targets may not be achievable with standard vancomycin doses, even though these isolates are reported as \"susceptible\" by Clinical Laboratory Standards Institute (CLSI) standards [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In such situations, alternate therapies should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    include rash, infusion-related reactions, nephrotoxicity, and ototoxicity. As noted above, vancomycin undergoes limited absorption when administered orally. However, among patients with colonic inflammation (a common occurrence in the setting of Clostridium difficile infection) the bioavailability of oral vancomycin may be increased. Therefore, systemic absorption of oral vancomycin can cause adverse effects similar to those observed in the setting of parenteral administration, including red man syndrome and maculopapular rash [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Red man syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red man syndrome is a histamine-mediated flushing during or immediately following infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . Flushing usually involves the face and neck, but can involve the entire body. It may be reduced or eliminated by avoiding excessive doses and prolonging the infusion time (eg, administering at a rate of no more than 500",
"    <span class=\"nowrap\">",
"     mg/hour)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/23\">",
"     23",
"    </a>",
"    ]. Red man syndrome and vancomycin hypersensitivity reactions are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link&amp;anchor=H2#H2\">",
"     \"Vancomycin hypersensitivity\", section on 'Red man syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotoxic potential of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    monotherapy is not fully understood. Early preparations of vancomycin were associated with nephrotoxicity, and some studies of present-day formulations have noted that 5 to 15 percent of patients treated with vancomycin alone develop an acute decline in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Nephrotoxicity associated with vancomycin monotherapy is not common, but increasing vancomycin troughs have been correlated with nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/16,28-30\">",
"     16,28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal insufficiency due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    administered concomitantly with an aminoglycoside is well established [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/24,27,31\">",
"     24,27,31",
"    </a>",
"    ]. The incidence of acute renal failure in this setting may be as high as 20 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/24,27,31\">",
"     24,27,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ototoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    -induced ototoxicity has been described, although few clinical studies have included serial audiometric testing with vancomycin administration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. One study of audiology screening including 130 newborns who received vancomycin failed to demonstrate an association between vancomycin use and ototoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/34\">",
"     34",
"    </a>",
"    ]. Reported risk factors for vancomycin-induced ototoxicity include preexisting hearing problems, underlying renal dysfunction, and older age, although there are few data to support these risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/31,35,36\">",
"     31,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIAL DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is based the type of infection along with patient weight and renal function. While published algorithms exist to guide practitioners in determining initial optimal dosing, comparisons regarding the accuracy of these algorithms illustrate their limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In addition, many of these algorithms were not intended to achieve the serum concentrations targets desired in certain clinical circumstances. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Target troughs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Routine administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    doses of 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    should be administered every 12 hours in patients with normal renal function, not to exceed 2 g per dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/37\">",
"     37",
"    </a>",
"    ]. In settings where rapid clearance is anticipated (such as in burn patients), the dose may be administered every eight hours. For rapid achievement of target concentrations in seriously ill patients, a loading dose of 25 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    may be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/2,3,38\">",
"     2,3,38",
"    </a>",
"    ]. This may also be appropriate for patients with critical illness in the setting of high anticipated volume of distribution (such as patients with serious burns or fluid overload).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    dosing is based on actual body weight (even in the setting of obesity), and doses are rounded to the nearest 250 mg. In general the drug should be infused over 0.5 hours for each 500 mg increment (example, 500 mg over 0.5 hours, 1000 mg over 1 hour, etc). In the setting of red man syndrome, the rate of infusion may be reduced to 500 mg over 1 hour.",
"   </p>",
"   <p>",
"    Randomized studies of continuous infusion regimens have not demonstrated substantial improvement in patient outcomes compared with intermittent dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/2\">",
"     2",
"    </a>",
"    ]. It is possible that use of continuous infusion may be associated with reduction in nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/39\">",
"     39",
"    </a>",
"    ], though adequately powered efficacy trials are lacking in most invasive infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with routine administration, initial dosing for obese patients of 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/40\">",
"     40",
"    </a>",
"    ]. To avoid individual doses greater than 2 g, the total daily dose (approximately 30",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    can be divided into three administrations (eg, every eight hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/41\">",
"     41",
"    </a>",
"    ]. The rate of infusion can also be adjusted as outlined above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Initial dosing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Impaired renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with renal insufficiency, doses in the range of 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (based on target trough concentration) rounded to the nearest 250 mg should be administered at frequencies based on estimations of creatinine clearance (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?29/57/30609?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef60466 \" href=\"UTD.htm?15/5/15454\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial dosing and subsequent monitoring in the setting of hemodialysis is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Hemodialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SERUM CONCENTRATION MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    serum concentration monitoring continues to be the subject of ongoing debate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Controlled clinical data in humans regarding treatment outcomes and toxicities relative to serum concentrations are sparse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Troughs versus peaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human data are lacking to establish relationships between treatment outcomes and trough concentrations. However, trough concentrations are useful as a surrogate to AUC and are generally considered the most accurate and practical method to monitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . Therefore, optimal dosing is guided by knowledge of both pathogen susceptibility and trough concentration.",
"   </p>",
"   <p>",
"    There is little role for the routine monitoring of peak",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    concentrations, given the concentration-independent pharmacodynamic properties of vancomycin and the lack of data correlating peak concentrations with either efficacy or toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/44\">",
"     44",
"    </a>",
"    ]. Although the 2005 guidelines on endocarditis endorsed by the Infectious Diseases Society of America (IDSA) identify target peak vancomycin concentrations of 30 to 45",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    this consensus opinion was based on animal models and in vitro susceptibility data rather than clinical evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Target troughs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    trough concentrations of at least 10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    should be achieved; this may reduce the emergence of isolates with elevated vancomycin minimum inhibitory concentrations (MICs) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Isolates with elevated MICs to vancomycin may also demonstrate reduced susceptibility to other antimicrobials (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    , dalbavancin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/42/27301?source=see_link\">",
"     telavancin",
"    </a>",
"    ). Therefore, attention to target levels may also be important for maintaining efficacy of other classes of antimicrobial agents.",
"   </p>",
"   <p>",
"    In the setting of invasive infections (such as bacteremia, endocarditis, osteomyelitis, prosthetic joint infections, hospital acquired pneumonia, and infections involving the central nervous system), many favor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    trough concentrations of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/37,44\">",
"     37,44",
"    </a>",
"    ]. Such concentrations generally achieve an",
"    <span class=\"nowrap\">",
"     AUC/MIC",
"    </span>",
"    of &ge;400 for isolates with vancomycin MIC &le;1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For treatment of infection due to isolates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    MICs &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    trough concentrations of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    should also be considered. However, if the MIC is &ge;2",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    a targeted",
"    <span class=\"nowrap\">",
"     AUC/MIC",
"    </span>",
"    of &ge;400 is not achievable with conventional dosing methods in patients with normal renal function. In such situations, alternate therapies should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Whom to monitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum trough concentration monitoring should be performed in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    therapy longer than three days. Once target concentrations are achieved, the trough vancomycin concentration should be monitored at least weekly for patients in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/19,48\">",
"     19,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with invasive infections receiving a prolonged course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      with target trough concentrations 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Patients with fluctuating renal function, fluctuating fluid balance, hemodynamic instability, critical illness, morbid obesity, or receiving dialysis",
"     </li>",
"     <li>",
"      Patients at increased risk of nephrotoxicity due to use of concomitant nephrotoxins such as aminoglycosides",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeat",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    trough concentrations need not be monitored in hemodynamically stable patients with stable renal function who are not included in the above categories once the target serum concentration has been achieved.",
"   </p>",
"   <p>",
"    Patients receiving oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for the treatment of Clostridium difficile infection do not require serum concentration monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Timing of levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trough concentrations should be measured within 30 minutes prior to infusion of the fourth or fifth dose following the initial dose or dose adjustment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/37\">",
"     37",
"    </a>",
"    ]. The time of the blood draw and the time of the previous infusion (initiation and completion) should be noted on the laboratory requisition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dose adjustments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictions for dose adjustments based upon serum concentrations are best performed after determination of individual pharmacokinetic parameters based on the following guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher than targeted trough concentrations require prolongation of the dosing interval",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reduction in dose. Peak levels will also be reduced unless the dose is modified. Reductions in dose without changes in the interval will result in proportional changes in trough concentrations. As an example, decreasing the dose by 25 percent will decrease the trough concentrations by approximately 25 percent (assuming steady renal function).",
"     </li>",
"     <li>",
"      Lower than targeted trough concentrations require either an increase in the dose or a reduction in the dose interval. Increases in dose without changes in the interval will result in proportional changes in trough concentrations. As an example, increasing the dose by 25 percent will increase the trough concentrations by approximately 25 percent (assuming steady renal function).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Subsequent management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatinine concentration should be determined daily until stable, then at least weekly thereafter. More intensive monitoring may be considered if renal function is unstable, if nephrotoxic drugs are administered concomitantly (eg, aminoglycosides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ), or if higher trough concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (ie, 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    are targeted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients on hemodialysis, a single initial dose of 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    should be administered following hemodialysis. The dry weight should be used in calculating the dose (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?28/21/29009?source=see_link\">",
"     calculator 2",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?28/26/29089?source=see_link\">",
"     calculator 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The approach subsequent dosing depends upon the method and frequency of dialysis.",
"   </p>",
"   <p>",
"    For patients receiving hemodialysis via older, less permeable low flux membranes, supplemental doses are usually not required post-dialysis. Therefore, subsequent dosing 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    should be repeated when the target trough concentration is achieved (usually between four and seven days) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/1,51\">",
"     1,51",
"    </a>",
"    ]. \"Spot\" serum concentration monitoring during this time may help identify the optimal interval in such settings.",
"   </p>",
"   <p>",
"    For patients undergoing hemodialysis via the newer, more permeable high-flux membranes, repeat",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    dosing is most often required following each session [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/1,51,52\">",
"     1,51,52",
"    </a>",
"    ]. The optimal approach to supplemental dosing post-dialysis in such settings is not certain. Previously, supplemental doses of at least 500 mg following each hemodialysis session were favored, although such fixed supplemental doses may result in a broad range of trough concentrations (ie, 5 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/53\">",
"     53",
"    </a>",
"    ]. This dosing approach may be inadequate for patients receiving prolonged courses of vancomycin for serious infections (such as osteomyelitis or endocarditis) with high target troughs (15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL).",
"    </span>",
"   </p>",
"   <p>",
"    Subsequently, initial weight-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    dosing for patients undergoing high-flux hemodialysis has been studied utilizing the following initial and post-dialysis doses (respectively): patients &lt;70 kg, 1000 mg followed by 500 mg; patients 70 to 100 kg, 1250 mg followed by 750 mg; patients &gt;100 kg, 1500 mg followed by 1000 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/52\">",
"     52",
"    </a>",
"    ]. Simulated or measured predialysis trough concentrations between 10 and 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    were achieved in 76.9 percent and 65.5 percent of post-load and maintenance doses, respectively.",
"   </p>",
"   <p>",
"    Serum concentrations assessed immediately prior to hemodialysis may also be used to guide subsequent dosing as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the prehemodialysis",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      concentration is within the target range, a supplemental dose of 500 mg should be administered.",
"     </li>",
"     <li>",
"      If the prehemodialysis",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      level is below the target range, a supplemental dose of 750 to 1000 mg should be administered.",
"     </li>",
"     <li>",
"      If the prehemodialysis",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      level is significantly above the target range, no supplemental dose should be given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the predialysis",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    concentration is outside the target range, a repeat vancomycin concentration should be checked at the next hemodialysis session. Adjustments can then be made according to the principles above. Once the prehemodialysis vancomycin concentration is within the target range, a predialysis vancomycin concentration should be checked weekly; if subsequent levels are outside the target range, adjustments to supplemental dosing should be made as outlined above.",
"   </p>",
"   <p>",
"    Longer intervals between hemodialysis sessions (eg, 72 hours rather than 48, occurring over a weekend) may result in lower prehemodialysis",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    concentrations at the first weekly session. In such settings higher supplemental doses (usually increased by 250 mg) at the last weekly hemodialysis session may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?14/47/15096/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      dosing requires consideration of the infection site, patient weight, renal function, and pathogen susceptibility. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      is restricted to parenteral administration for the treatment of systemic infections. It is distributed widely to various tissues and body fluids, with a volume of distribution ranging from 0.4 to 1.0",
"      <span class=\"nowrap\">",
"       L/kg.",
"      </span>",
"      Penetration of vancomycin may vary by site and concomitant disease states. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In vitro and animal model studies describing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      pharmacodynamics indicate the rate of killing depends primarily upon time of concentration exceeding the organism's minimum inhibitory concentration (MIC). The area under the time concentration curve (AUC:MIC ratio) is the best predictor of efficacy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      potentially related to dosing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rate of administration include infusion-related reactions, nephrotoxicity. and ototoxicity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      dosing of 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      should be administered to patients with normal renal function, impaired renal function",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      obesity. For rapid achievement of target concentrations in seriously-ill patients, a loading dose of 25 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      may be administered. Maintenance dosing and dosing frequency should be determined based on weight and creatinine clearance (",
"      <a class=\"graphic graphic_table graphicRef60466 \" href=\"UTD.htm?15/5/15454\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      trough concentrations of at least 10",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      should be achieved. In the setting of invasive infections (such as endocarditis, osteomyelitis, prosthetic joint infections and infections involving the central nervous system), many favor vancomycin trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Target troughs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum trough concentration monitoring should be performed in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      therapy longer than three days. Once target concentrations are achieved, the trough vancomycin concentration should be monitored at least weekly for patients in the circumstances outlined above. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Whom to monitor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients on hemodialysis, a single initial dose of 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      should be administered following hemodialysis. For patients undergoing hemodialysis via the newer, more permeable high flux membranes, repeat",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      dosing is often required following each session as described above. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/1\">",
"      Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/2\">",
"      Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/3\">",
"      Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/4\">",
"      Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/5\">",
"      Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/6\">",
"      Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part IV: Vancomycin. Clin Pharmacokinet 1991; 20:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/7\">",
"      Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/8\">",
"      Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/9\">",
"      Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/10\">",
"      Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/11\">",
"      Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/12\">",
"      Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/13\">",
"      Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/14\">",
"      Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/15\">",
"      Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/16\">",
"      Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/17\">",
"      Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/18\">",
"      Sakoulas G, Gold HS, Cohen RA, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006; 57:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/19\">",
"      Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/20\">",
"      Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/21\">",
"      Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008; 14:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/22\">",
"      Osawa R, Kaka AS. Maculopapular rash induced by oral vancomycin. Clin Infect Dis 2008; 47:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/23\">",
"      Polk RE, Israel D, Wang J, et al. Vancomycin skin tests and prediction of \"red man syndrome\" in healthy volunteers. Antimicrob Agents Chemother 1993; 37:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/24\">",
"      Appel GB, Given DB, Levine LR, Cooper GL. Vancomycin and the kidney. Am J Kidney Dis 1986; 8:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/25\">",
"      Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1988; 3:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/26\">",
"      Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/27\">",
"      Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/28\">",
"      Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/29\">",
"      Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/30\">",
"      Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/31\">",
"      Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/32\">",
"      Klibanov OM, Filicko JE, DeSimone JA Jr, Tice DS. Sensorineural hearing loss associated with intrathecal vancomycin. Ann Pharmacother 2003; 37:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/33\">",
"      Cohen E, Dadashev A, Drucker M, et al. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 2002; 49:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/34\">",
"      de Hoog M, van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003; 142:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/35\">",
"      Brummett RE. Ototoxicity of vancomycin and analogues. Otolaryngol Clin North Am 1993; 26:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/36\">",
"      Brummett RE, Fox KE, Jacobs F, et al. Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. Arch Otolaryngol Head Neck Surg 1990; 116:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/37\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/38\">",
"      Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006; 42:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/39\">",
"      Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 67:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/40\">",
"      Hall RG 2nd, Payne KD, Bain AM, et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 2008; 121:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/41\">",
"      Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/42\">",
"      Cant&uacute; TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/43\">",
"      Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993; 27:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/44\">",
"      Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/45\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/46\">",
"      Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/47\">",
"      Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/48\">",
"      Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/49\">",
"      Vandecasteele SJ, De Bacquer D, De Vriese AS. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis. Clin Infect Dis 2011; 53:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/50\">",
"      Brown M, Polisetty R, Gracely EJ, et al. Weight-based loading of vancomycin in patients on hemodialysis. Clin Infect Dis 2011; 53:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/51\">",
"      Quale JM, O'Halloran JJ, DeVincenzo N, Barth RH. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother 1992; 36:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/52\">",
"      Zelenitsky SA, Ariano RE, McCrae ML, Vercaigne LM. Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis. Clin Infect Dis 2012; 55:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/47/15096/abstract/53\">",
"      Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm 2004; 61:1812.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 484 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15096=[""].join("\n");
var outline_f14_47_15096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Red man syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIAL DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Routine administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Impaired renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SERUM CONCENTRATION MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Troughs versus peaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Target troughs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Whom to monitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Timing of levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dose adjustments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Subsequent management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/484\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/484|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/5/15454\" title=\"table 1\">",
"      Dosing for vancomycin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?29/57/30609?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?28/21/29009?source=related_link\" title=\"calculator 2\">",
"      Calculator: Lean body weight (adult male)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?28/26/29089?source=related_link\" title=\"calculator 3\">",
"      Calculator: Lean body weight (adult female)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_47_15097="Sodium chloride preparations (saline and oral salt tablets): Drug information";
var content_f14_47_15097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium chloride preparations (saline and oral salt tablets): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/28/39366?source=see_link\">",
"    see \"Sodium chloride preparations (saline and oral salt tablets): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/41/36503?source=see_link\">",
"    see \"Sodium chloride preparations (saline and oral salt tablets): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      4-Way&reg; Saline Moisturizing Mist [OTC];",
"     </li>",
"     <li>",
"      Altachlore [OTC];",
"     </li>",
"     <li>",
"      Altamist [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Allergy &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Baby Saline [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline Nasal Gel [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline No-Drip [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline [OTC];",
"     </li>",
"     <li>",
"      Deep Sea [OTC];",
"     </li>",
"     <li>",
"      Entsol&reg; [OTC];",
"     </li>",
"     <li>",
"      HuMist&reg; [OTC];",
"     </li>",
"     <li>",
"      HyperSal&reg;;",
"     </li>",
"     <li>",
"      Little Noses&reg; Saline [OTC];",
"     </li>",
"     <li>",
"      Little Noses&reg; Sterile Saline Nasal Mist [OTC];",
"     </li>",
"     <li>",
"      Little Noses&reg; Stuffy Nose Kit [OTC];",
"     </li>",
"     <li>",
"      Muro 128&reg; [OTC];",
"     </li>",
"     <li>",
"      Na-Zone&reg; [OTC];",
"     </li>",
"     <li>",
"      NebuSal&trade;;",
"     </li>",
"     <li>",
"      Ocean&reg; for Kids [OTC];",
"     </li>",
"     <li>",
"      Ocean&reg; [OTC];",
"     </li>",
"     <li>",
"      Pretz&reg; [OTC];",
"     </li>",
"     <li>",
"      Rhinaris&reg; [OTC];",
"     </li>",
"     <li>",
"      Safe Wash&trade; [OTC];",
"     </li>",
"     <li>",
"      Saline Mist [OTC];",
"     </li>",
"     <li>",
"      Saljet&reg; [OTC];",
"     </li>",
"     <li>",
"      Sea Soft Nasal Mist [OTC];",
"     </li>",
"     <li>",
"      Simply Saline&reg; Baby [OTC];",
"     </li>",
"     <li>",
"      Simply Saline&reg; [OTC];",
"     </li>",
"     <li>",
"      Sochlor&trade; [OTC];",
"     </li>",
"     <li>",
"      Syrex;",
"     </li>",
"     <li>",
"      Wound Wash Saline&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Parenteral;",
"     </li>",
"     <li>",
"      Genitourinary Irrigant;",
"     </li>",
"     <li>",
"      Irrigant;",
"     </li>",
"     <li>",
"      Lubricant, Ocular;",
"     </li>",
"     <li>",
"      Sodium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refractory elevated ICP due to various etiologies (eg, subarachnoid hemorrhage, trauma, neoplasm), transtentorial herniation syndromes (unlabeled use):",
"     </b>",
"     I.V.: Hypertonic saline: 23.4% (30-60 mL) given over 2-20 minutes administered via central venous access only (Koenig, 2008; Suarez, 1998; Ware, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Subarachnoid hemorrhage with hyponatremia (ie, &le;135 mEq/L) to enhance cerebral perfusion (unlabeled use):",
"     </b>",
"     I.V.: Hypertonic saline: 3% sodium chloride/acetate (50:50 mixture) 100-200 mL/hour administered via central venous catheter; titrate to clinical response up to a maximum serum sodium between 150-160 mEq/L (achieved at a rate of 0.5-1 mEq/L/hour) (Suarez, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Traumatic brain injury with elevated ICP (unlabeled use):",
"     </b>",
"     I.V.: Hypertonic saline:",
"     <b>",
"      Note:",
"     </b>",
"     Optimal dose has not been established; due to insufficient evidence, the Brain Trauma Foundation guidelines (Bratton, 2007) do not make specific recommendations on the use of hypertonic saline for the treatment of traumatic intracranial hypertension. Clinical trials are small; few are prospective.",
"     <b>",
"      Some concentrations may not be commercially available; administer via central venous catheter;",
"     </b>",
"     protocols include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3%: 300 mL administered over 20 minutes when ICP values exceed 20 mm Hg (Huang, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.2%: 1.5 mL/kg administered over 15 minutes when ICP values exceed 15 mm Hg (Munar, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5%: 2 mL/kg administered over 20 minutes when ICP values exceed 25 mm Hg (Vialet, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     23.4%: 30 mL administered over 2 minutes (Ware, 2005)",
"     <b>",
"      or",
"     </b>",
"     over &gt;30 minutes when ICP values exceed 20 mm Hg (Kerwin, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GU irrigant:",
"     </b>",
"     Irrigation: 1-3 L/day by intermittent irrigation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Replacement:",
"     </b>",
"     I.V.: Determined by laboratory determinations mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyponatremia:",
"     </b>",
"     Sodium deficiency (mEq/kg) = [% dehydration (L/kg)/100 x 70 (mEq/L)] + [0.6 (L/kg) x (140 - serum sodium) (mEq/L)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      To correct acute, serious hyponatremia:",
"     </i>",
"     mEq sodium = [desired sodium (mEq/L) - actual sodium (mEq/L)] x [0.6 x wt (kg)]; for acute correction use 125 mEq/L as the desired serum sodium; acutely correct serum sodium in 5 mEq/L/dose increments; more gradual correction in increments of 10 mEq/L/day is indicated in the asymptomatic patient",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Approximate Deficits of Water and Electrolytes in Moderately Severe Dehydration",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"left\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"115\">",
"     </col>",
"     <col align=\"center\" width=\"115\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Condition",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Water",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL/kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Sodium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/kg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         A",
"         <b>",
"          negative",
"         </b>",
"         deficit indicates total body",
"         <b>",
"          excess",
"         </b>",
"         prior to treatment.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Adapted from Behrman RE, Kleigman RM, Nelson WE, et al, eds,",
"         <i>",
"          Nelson Textbook of Pediatrics",
"         </i>",
"         , 14th ed, WB Saunders Co, 1992.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Fasting and thirsting",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Diarrhea",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         isonatremic",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         hypernatremic",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         hyponatremic",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-12",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Pyloric stenosis",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Diabetic acidosis",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9-10",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ointment: Apply once daily or more often",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution: Instill 1-2 drops into affected eye(s) every 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchodilator diluent:",
"     </b>",
"     Inhalation: 1-3 sprays (1-3 mL) to dilute bronchodilator solution in nebulizer before administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nasal congestion:",
"     </b>",
"     Intranasal: 2-3 sprays in each nostril as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Irrigation:",
"     </b>",
"     Spray affected area",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/41/36503?source=see_link\">",
"      see \"Sodium chloride preparations (saline and oral salt tablets): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyponatremia:",
"     </b>",
"     I.V.: Children: Hypertonic solutions (&gt;0.9%) should only be used for the initial treatment of acute serious symptomatic hyponatremia or increased intracranial pressure in the setting of traumatic brain injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     3-4 mEq/kg/day; maximum: 100-150 mEq/day; dosage varies widely depending on clinical condition",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Replacement:",
"     </i>",
"     Determined by laboratory determinations mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sodium deficiency (mEq/kg) = [% dehydration (L/kg)/100 x 70 (mEq/L)] + [0.6 (L/kg) x (140 - serum sodium) (mEq/L)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Increased intracranial pressure (unlabeled use):",
"     </b>",
"     Hypertonic saline (3%): 0.1-1 mL/kg/hour continuous infusion titrated to maintain ICP &lt;20 mm Hg (Addleson, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Irrigation: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2016668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, intranasal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entsol&reg;: 3% (100 mL) [chlorofluorocarbon free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Noses&reg; Sterile Saline Nasal Mist: 0.9% (50 mL) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Safe Wash&trade;: 0.9% (210 mL) [chlorofluorocarbon free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline: &lt;0.5% (14 g) [contains aloe, soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entsol&reg;: 3% (20 g [DSC]) [contains aloe, benzalkonium chloride, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinaris&reg;: 0.2% (28.4 g) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline No-Drip: &lt;0.5% (22 mL) [contains aloe, benzalkonium chloride, benzyl alcohol, soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.45% (50 mL, 100 mL, 250 mL, 500 mL, 1000 mL); 0.9% (25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, 1000 mL); 3% (500 mL); 5% (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.9% (2 mL, 3 mL, 5 mL, 10 mL, 20 mL, 50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [I.V. flush, preservative free]: 0.9% (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL, 50 mL, 125 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Syrex: 0.9% (2.5 mL, 3 mL, 5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [bacteriostatic]: 0.9% (10 mL, 20 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 14.6% (20 mL, 40 mL); 23.4% (100 mL, 250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 14.6% (20 mL, 40 mL); 23.4% (30 mL, 100 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: 5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altachlore: 5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sochlor&trade;: 5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Muro 128&reg;: 5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, intranasal [concentrate, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pretz&reg;: 1 teaspoon/dose (360 g) [with yerba santa]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for blood processing [not for injection]: 0.9% (3000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for inhalation [preservative free]: 0.9% (3 mL, 5 mL, 15 mL); 3% (15 mL); 10% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for irrigation: 0.9% (250 mL, 500 mL, 1000 mL, 1500 mL, 2000 mL, 3000 mL, 4000 mL, 5000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for irrigation [preservative free]: 0.9% (250 mL, 500 mL, 1000 mL, 1500 mL, 2000 mL, 3000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for irrigation [slush solution]: 0.9% (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization [preservative free]: 3% (4 mL); 7% (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyperSal&reg;: 3.5% (4 mL); 7% (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NebuSal&trade;: 6% (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simply Saline&reg;: 3% (44 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [buffered/spray, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pretz&reg;: 0.75% (20 mL) [chlorofluorocarbon free; with yerba santa]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline: 0.65% (50 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [drops/mist/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HuMist&reg;: 0.65% (45 mL) [ethanol free; contains chlorobutanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocean&reg;: 0.65% (45 mL, 104 mL, 473 mL) [contains benzalkonium chloride, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocean&reg; for Kids: 0.65% (37.5 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [drops/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Baby Saline: 0.65% (30 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Noses&reg; Saline: 0.65% (30 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Noses&reg; Stuffy Nose Kit: 0.65% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [irrigation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pretz&reg;: 0.75% (960 mL) [contains benzalkonium chloride, sodium benzoate; with yerba santa]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [isotonic, buffered/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pretz&reg;: 0.75% (50 mL) [contains benzalkonium chloride, sodium benzoate; with yerba santa]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [mist]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-Way&reg; Saline Moisturizing Mist: 0.74% (29.6 mL) [ethanol free; contains benzalkonium chloride, menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Allergy &amp; Sinus: 2.65% (50 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline: 0.65% (50 mL) [ethanol free; contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entsol&reg;: 3% (30 mL [DSC]) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rhinaris&reg;: 0.2% (30 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saline Mist: 0.65% (45 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sea Soft Nasal Mist: 0.65% (45 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [mist, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simply Saline&reg;: 0.9% (44 mL, 90 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simply Saline&reg; Baby: 0.9% (45 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [nasal wash, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entsol&reg;: 3% (240 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]: 0.65% (44 mL, 88 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altamist: 0.65% (60 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Deep Sea: 0.65% (44 mL) [contains benzalkonium chloride, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Na-Zone&reg;: 0.65% (60 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altachlore: 5% (15 mL, 30 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Muro 128&reg;: 2% (15 mL); 5% (15 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sochlor&trade;: 5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saljet&reg;: 0.9% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wound Wash Saline&trade;: 0.9% (90 mL, 210 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swab, intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ayr&reg; Saline Nasal Gel: 0.65% (20s) [contains aloe, benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, topical: 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes aerosol, gel, powder for solution, swab",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4052605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation solution: Do not warm &gt;66&deg;C (150&deg;F); not for I.V. use.  Wound Wash Saline&trade;: Before use, expel a short stream into air to clear nozzle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: &ge;3% solutions: Administration through a central line is recommended due to high osmolarity and tonicity",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F221694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in fat emulsion 10%, mannitol 20%, mannitol 25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Ciprofloxacin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cimetidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Restores sodium ion in patients with restricted oral intake (especially hyponatremia states or low salt syndrome).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concentrated sodium chloride: Additive for parenteral fluid therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypertonic sodium chloride: For severe hyponatremia and hypochloremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypotonic sodium chloride: Hydrating solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal saline: Restores water/sodium losses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Reduces corneal edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Restores moisture to pulmonary system; loosens and thins congestion caused by colds or allergies; diluent for bronchodilator solutions that require dilution before inhalation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Restores moisture to nasal membranes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Irrigation: Wound cleansing, irrigation, and flushing",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F221685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Hypertonic saline: Refractory elevated intracranial pressure (ICP) due to various etiologies (eg, subarachnoid hemorrhage,  neoplasm); transtentorial herniation syndrome; traumatic brain injury with elevated ICP.",
"     <b>",
"      Note:",
"     </b>",
"     May be used in patients in whom mannitol may not be recommended (eg, renal failure).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F221696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation &gt;0.9% concentration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Per The Joint Commission (TJC) recommendations, concentrated electrolyte solutions (eg, NaCl &gt;0.9%) should not be available in patient care areas.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       Inappropriate use of low sodium or sodium-free intravenous fluids (eg, D",
"       <sub>",
"        5",
"       </sub>",
"       W, hypotonic saline) in pediatric patients can lead to significant morbidity and mortality due to hyponatremia (ISMP, 2009).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Congestive heart failure, transient hypotension (especially with adult administration of 23.4% NaCl)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Central pontine myelinolysis (due to rapid correction of hyponatremia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dilution of serum electrolytes, extravasation, hypernatremia, hypervolemia, hypokalemia, overhydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting (oral use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombosis, phlebitis, extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm (inhalation with hypertonic solutions), pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium chloride or any component of the formulation; hypertonic uterus, hypernatremia, fluid retention",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyponatremia: Administration of low sodium or sodium-free I.V. solutions may result in significant hyponatremia or water intoxication in pediatric patients; monitor serum sodium concentration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium toxicity: Is almost exclusively related to how fast a sodium deficit is corrected; both rate and magnitude are extremely important.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cirrhosis: Use with caution in patients with cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: Use with caution in patients with edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may cause sodium retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacteriostatic sodium chloride: Do not use bacteriostatic sodium chloride in newborns since benzyl alcohol preservatives have been associated with toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irrigants: For external use only; not for parenteral use. Do not use during electrosurgical procedures. Irrigating fluids may be absorbed into systemic circulation; monitor for fluid or solute overload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound Wash Saline&trade;: For single-patient use only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Sodium Chloride may increase the excretion of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: Sodium Chloride may enhance the adverse/toxic effect of Tolvaptan. Specifically, Hypertonic Saline may increase the risk for too rapid of an increase in serum sodium concentrations.  Management: This interaction is specific to Hypertonic Saline.  Avoid concurrent use of Hypertonic Saline with Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Sodium requirements do not change during pregnancy (IOM, 2004). Nasal saline rinses may be used for the treatment of pregnancy rhinitis (Wallace, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13888260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13888259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Sodium is found in breast milk. Sodium requirements do not change during lactation (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F221673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Broncho Saline Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (90 mL): $5.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Simply Saline Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (44 mL): $4.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Rhinaris Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (28.4 g): $4.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (HyperSal Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5% (4 mL): $0.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (4 mL): $0.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Nebusal Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6% (4 mL): $0.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Sodium Chloride Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45% (3 mL): $0.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (3 mL): $0.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (4 mL): $0.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (4 mL): $0.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (4 mL): $0.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Altachlore Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (3.5 g): $13.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Muro 128 Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (3.5 g): $18.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Sodium Chloride (Hypertonic) Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (3.5 g): $12.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (AYR Saline Nasal Rinse Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.57 g (50): $7.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Altachlore Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (15 mL): $17.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Argyle Sterile Saline Irrigation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (100 mL): $1.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ARY Nasal Mist Allergy/Sinus Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.65% (50 mL): $3.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ayr Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (50 mL): $2.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ayr Saline Nasal Drops Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (50 mL): $2.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Baby Ayr Saline Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (30 mL): $2.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Entsol Nasal Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (100 mL): $32.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Humist Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (45 mL): $1.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Little Noses Decongestant Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125% (15 mL): $3.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Little Noses Saline Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (30 mL): $2.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Little Noses Stuffy Nose Kit Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (15 mL): $3.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Monoject PreFill Advanced NaCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (10 mL): $1.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Monoject PreFill Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (3 mL): $3.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Monoject Sodium Chloride Flush Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (3 mL): $0.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Muro 128 Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (15 mL): $17.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (15 mL): $18.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NasaDrops Saline on the Go Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (15 mL): $0.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nasal Moist Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (15 mL): $2.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ocean for Kids Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (37.5 mL): $3.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ocean Nasal Spray Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (45 mL): $3.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optics Eye Wash Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (20 mL): $0.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pretz)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (360 g): $15.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rhinaris Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (30 mL): $6.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Safe Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (210 mL): $6.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Saline Bacteriostatic Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (30 mL): $1.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Saline Nasal Spray Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.65% (45 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Saline-Benzyl Alcohol Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (10 mL): $1.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Saljet External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (30 mL): $0.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Saljet Rinse External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (30 mL): $0.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Chloride (Hypertonic) Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (15 mL): $10.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Chloride Flush Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (10 mL): $0.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Chloride Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (10 mL): $0.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mEq/mL (40 mL): $1.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Chloride Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45% (500 mL): $1.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (100 mL): $2.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (500 mL): $2.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mEq/mL (100 mL): $3.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (500 mL): $3.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Chloride Thermoject Sys Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (10 mL): $8.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (SwabFlush Saline Flush Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (10 mL): $1.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Wound Wash Saline External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (210 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet,Dispersible",
"     </b>",
"     (Sodium Chloride External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (1000): $98.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sodium Chloride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (100): $8.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F221663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum sodium, potassium, chloride, and bicarbonate concentrations; I &amp; O, weight",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F221666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum/plasma sodium concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Full-term: 133-142 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature: 132-140 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 months to Adults: 135-145 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chlorek Sodowy 24Na (PL);",
"     </li>",
"     <li>",
"      Hiperton (MX);",
"     </li>",
"     <li>",
"      Inj. natrii chlorati isotonica (PL);",
"     </li>",
"     <li>",
"      Miwana (PL);",
"     </li>",
"     <li>",
"      Natrii chloridum 0,9% solutio pro irrigatione (PL);",
"     </li>",
"     <li>",
"      Natrium chloratum (PL);",
"     </li>",
"     <li>",
"      Oftarinol (PL);",
"     </li>",
"     <li>",
"      Physiodose (PL);",
"     </li>",
"     <li>",
"      Sensitive Eyes Saline Solution (PL);",
"     </li>",
"     <li>",
"      Sodium Chloride (PL);",
"     </li>",
"     <li>",
"      Solnasin (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Principal extracellular cation; functions in fluid and electrolyte balance, osmotic pressure control, and water distribution",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine; also sweat, tears, saliva",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adelson PD, Bratton SL, Carney NA, et al, &ldquo;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents. Chapter 11. Use of Hyperosmolar Therapy in the Management of Severe Pediatric Traumatic Brain Injury,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2003, 4(3 Suppl):40-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/12847347/pubmed\" id=\"12847347\" target=\"_blank\">",
"        12847347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badjatia N, Carney N, Crocco TJ, et al, &ldquo;Guideline for Prehospital Management of Traumatic Brain Injury 2nd Edition,&rdquo;",
"      <i>",
"       Prehosp Emerg Care",
"      </i>",
"      , 2008, 12(Suppl 1):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/18203044/pubmed\" id=\"18203044\" target=\"_blank\">",
"        18203044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barer J, Hill LL, Hill RM, et al, &ldquo;Fatal Poisoning From Salt Used as an Emetic,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1973, 125(6):889-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/4708280/pubmed\" id=\"4708280\" target=\"_blank\">",
"        4708280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhardwaj A and Ulatowski JA, &ldquo;Hypertonic Saline Solutions in Brain Injury,&rdquo;",
"      <i>",
"       Curr Opin Crit Care",
"      </i>",
"      , 2004, 10(2):126-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/15075723/pubmed\" id=\"15075723\" target=\"_blank\">",
"        15075723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):1-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/17511534/pubmed\" id=\"17511534\" target=\"_blank\">",
"        17511534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation,\"Guidelines for the Field Management of Combat-Related Head Trauma,\" 2005. Available at file://www.braintrauma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broderick J, Connolly S, Feldmann E, et al, \"Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(6):2001-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/17478736/pubmed\" id=\"17478736\" target=\"_blank\">",
"        17478736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Finfer S, Bellomo R, Boyce N, et al, &ldquo;A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit. SAFE Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(22):2247-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/15163774/pubmed\" id=\"15163774\" target=\"_blank\">",
"        15163774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forsyth LL, Liu-DeRyke X, Parker D, et al, &ldquo;Role of Hypertonic Saline for the Management of Intracranial Hypertension After Stroke and Traumatic Brain Injury,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(4):469-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/18363531/pubmed\" id=\"18363531\" target=\"_blank\">",
"        18363531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gresham GS and Mashru MK, &ldquo;Fatal Poisoning With Sodium Chloride,&rdquo;",
"      <i>",
"       Forensic Sci Int",
"      </i>",
"      , 1982, 20:87-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/7095681/pubmed\" id=\"7095681\" target=\"_blank\">",
"        7095681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huang SJ, Chang L, Han YY, et al, &ldquo;Efficacy and Safety of Hypertonic Saline Solutions in the Treatment of Severe Head Injury,&rdquo;",
"      <i>",
"       Surg Neurol",
"      </i>",
"      , 2006, 65(6):539-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/16720165/pubmed\" id=\"16720165\" target=\"_blank\">",
"        16720165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice, &ldquo;Plain D",
"      <sub>",
"       5",
"      </sub>",
"      W or Hypotonic Saline Solutions Post-Op Could Result in Acute Hyponatremia and Death in Healthy Children,&rdquo;",
"      <i>",
"       ISMP Medication Safety Alert",
"      </i>",
"      , August 13, 2009. Available at file://www.ismp.org/Newsletters/acutecare/articles/20090813.asp",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate",
"      </i>",
"      , Washington, DC: National Academy Press, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joint Commission on Accreditation of Healthcare Organizations, &ldquo;2005 National Patient Safety Goals.&rdquo; Available at file://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/05_npsgs.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerwin AJ, Schinco MA, Tepas JJ 3rd, et al, &ldquo;The Use of 23.4% Hypertonic Saline for the Management of Elevated Intracranial Pressure in Patients With Severe Traumatic Brain Injury: A Pilot Study,&rdquo;",
"      <i>",
"       J Trauma",
"      </i>",
"      , 2009, 67(2):277-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/19667879/pubmed\" id=\"19667879\" target=\"_blank\">",
"        19667879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kochanek PM, Carney N, Adelson PD, et al, &ldquo;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents -- Second Edition,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2012, 13(Suppl 1):1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/22217782/pubmed\" id=\"22217782\" target=\"_blank\">",
"        22217782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koenig MA, Bryan M, Lewin JL 3rd, et al, &ldquo;Reversal of Transtentorial Herniation With Hypertonic Saline,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2008, 70(13):1023-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/18272864/pubmed\" id=\"18272864\" target=\"_blank\">",
"        18272864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meadow R, &ldquo;Nonaccidental Salt Poisoning,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1993, 68(4):448-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/8503665/pubmed\" id=\"8503665\" target=\"_blank\">",
"        8503665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moder KG and Hurley DL, &ldquo;Fatal Hypernatremia From Exogenous Salt Intake: Report of a Case and Review of the Literature,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1990, 65(12):1587-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/2255221/pubmed\" id=\"2255221\" target=\"_blank\">",
"        2255221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Munar F, Ferrer AM, de Nadal M, et al, &ldquo;Cerebral Hemodynamic Effects of 7.2% Hypertonic Saline in Patients With Head Injury and Raised Intracranial Pressure,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2000, 17(1):41-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/10674757/pubmed\" id=\"10674757\" target=\"_blank\">",
"        10674757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith EJ, and Palevsky S, &ldquo;Salt Poisoning in a Two-Year-Old Child,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1990, 8:571-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/2222612/pubmed\" id=\"2222612\" target=\"_blank\">",
"        2222612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suarez JI, Qureshi, AI, Bhardwaj A, et al, &ldquo;Treatment of Refractory Intracranial Hypertension With 23.4% Saline,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(6):1118-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/9635664/pubmed\" id=\"9635664\" target=\"_blank\">",
"        9635664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suarez JI, Qureshi AI, Parekh PD, et al, &ldquo;Administration of Hypertonic (3%) Sodium Chloride/Acetate in Hyponatremic Patients With Symptomatic Vasospasm Following Subarachnoid Hemorrhage,&rdquo;",
"      <i>",
"       J Neurosurg Anesthesiol",
"      </i>",
"      , 1999, 11(3):178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/10414672/pubmed\" id=\"10414672\" target=\"_blank\">",
"        10414672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tseng MY, Al-Rawi PG, Pickard JD, et al, &ldquo;Effect of Hypertonic Saline on Cerebral Blood Flow in Poor-Grade Patients With Subarachnoid Hemorrhage,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2003, 34(6):1389-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/12730557/pubmed\" id=\"12730557\" target=\"_blank\">",
"        12730557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbalis JG, Goldsmith SR, Greenberg A, et al, &ldquo;Hyponatremia Treatment Guidelines 2007: Expert Panel Recommendations,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2007 120 (11 Suppl 1):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/17981159/pubmed\" id=\"17981159\" target=\"_blank\">",
"        17981159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vialet R, Albanese J, Thomachot L, et al, &ldquo;Isovolume Hypertonic Solutes (Sodium Chloride or Mannitol) in the Treatment of Refractory Posttraumatic Intracranial Hypertension: 2 mL/kg 7.5% Saline is More Effective Than 2 mL/kg 20% Mannitol,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2003, 31(6):1683-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/12794404/pubmed\" id=\"12794404\" target=\"_blank\">",
"        12794404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace DV, Dykewicz MS, Bernstein DI, et al, \"The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2008, 122(2 Suppl):1-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/1866258/pubmed\" id=\"1866258\" target=\"_blank\">",
"        1866258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ware ML, Nemani VM, Meeker M, et al, &ldquo;Effects of 23.4% Sodium Chloride Solution in Reducing Intracranial Pressure in Patients With Traumatic Brain Injury: A Preliminary Study,&rdquo;",
"      <i>",
"       Neurosurgery",
"      </i>",
"      , 2005, 57(4):727-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/47/15097/abstract-text/16239885/pubmed\" id=\"16239885\" target=\"_blank\">",
"        16239885",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9929 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15097=[""].join("\n");
var outline_f14_47_15097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221678\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221688\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221680\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221684\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221681\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2016668\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221650\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4052605\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221694\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221667\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221685\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221696\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221686\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221671\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221654\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300053\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221659\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221661\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888258\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888260\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888259\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221673\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221663\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221666\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869407\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221653\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221670\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9929\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9929|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/28/39366?source=related_link\">",
"      Sodium chloride preparations (saline and oral salt tablets): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/41/36503?source=related_link\">",
"      Sodium chloride preparations (saline and oral salt tablets): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_47_15098="Lichen sclerosus - trunk";
var content_f14_47_15098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74154%7EDERM%2F79867%7EDERM%2F60332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74154%7EDERM%2F79867%7EDERM%2F60332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oval porcelain-white plaques are present on the trunk of this patient with extragenital lichen sclerosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A porcelain-white, finely wrinkled plaque is present on the breast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple white, atrophic plaques are present on the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15098=[""].join("\n");
var outline_f14_47_15098=null;
var title_f14_47_15099="Examples of medications associated with hair loss";
var content_f14_47_15099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of medications associated with telogen hair loss",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Acitretin",
"      </td>",
"      <td>",
"       Heavy metals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amantadine",
"      </td>",
"      <td>",
"       Hormones",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amiodarone",
"      </td>",
"      <td>",
"       Isotretinoin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anticoagulants",
"      </td>",
"      <td>",
"       Ketoconazole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anticonvulsants",
"      </td>",
"      <td>",
"       Lithium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Captopril",
"      </td>",
"      <td>",
"       Penicillamine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cholesterol lowering drugs",
"      </td>",
"      <td>",
"       Propanolol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cimetidine",
"      </td>",
"      <td>",
"       Valproic acid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Colchicine",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted and modified from: Litt JZ. Litt's Pocketbook of Drug Eruptions and Interactions, 3rd ed, The Parthenon Publishing Group, New York 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15099=[""].join("\n");
var outline_f14_47_15099=null;
var title_f14_47_15100="Cataract classification";
var content_f14_47_15100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of cataracts in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anterior polar",
"       </td>",
"       <td>",
"        Anterior poles; usually bilateral",
"       </td>",
"       <td>",
"        Often hereditary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent fetal vasculature",
"       </td>",
"       <td>",
"        Posterior; unilateral",
"       </td>",
"       <td>",
"        Associated with microphthalmia and glaucoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Posterior polar",
"       </td>",
"       <td>",
"        Unilateral posterior pole (Mittendorf dot)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral posterior pole",
"       </td>",
"       <td>",
"        May be associated with defects in the posterior capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior lentiglobus/lenticonus",
"       </td>",
"       <td>",
"        Posterior capsule; mainly unilateral",
"       </td>",
"       <td>",
"        Usually sporadic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior subcapsular",
"       </td>",
"       <td>",
"        Immediately anterior to posterior capsule",
"       </td>",
"       <td>",
"        Associated with inflammatory conditions, glucocorticoids use, ionizing radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total (diffuse, complete)",
"       </td>",
"       <td>",
"        Involve entire crystalline lens",
"       </td>",
"       <td>",
"        Usually seen after trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Zonular cataracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lamellar",
"       </td>",
"       <td class=\"sublist_other\">",
"        Layer of cortex peripheral to the Y sutures of the lens; usually bilateral",
"       </td>",
"       <td class=\"sublist_other\">",
"        May be hereditary (autosomal dominant) or acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nuclear",
"       </td>",
"       <td class=\"sublist_other\">",
"        Embryonal or fetal nucleus; unilateral or blateral",
"       </td>",
"       <td class=\"sublist_other\">",
"        Microphthalmia and microcornia are usually present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sutural",
"       </td>",
"       <td class=\"sublist_other\">",
"        Y sutures",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15100=[""].join("\n");
var outline_f14_47_15100=null;
var title_f14_47_15101="Persistence of middle ear effusion after AOM";
var content_f14_47_15101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Persistence of middle ear effusion after acute otitis media",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 288px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percent of children with&nbsp;middle ear effusion&nbsp;persisting for up to 12 weeks after an episode of acute otitis media.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:&nbsp;Bluestone CD,&nbsp;Klein JO,&nbsp;Otitis Media in Infants and Children,&nbsp;WB Saunders, Philadelphia 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15101=[""].join("\n");
var outline_f14_47_15101=null;
var title_f14_47_15102="Contents: Pediatric gynecology";
var content_f14_47_15102=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric gynecology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric gynecology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43316\">",
"           Gynecologic examination of the newborn and child",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inflammation and infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1032\">",
"           Clinical features and diagnosis of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11992\">",
"           Pathogenesis of and risk factors for pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/51/37689\">",
"           Sexually transmitted diseases: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35832\">",
"           Treatment of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26072\">",
"           Vulvovaginal complaints in the prepubertal child",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Menstrual issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25975\">",
"           Definition and evaluation of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11402\">",
"           Diagnosis and treatment of endometriosis in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11160\">",
"           Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14937\">",
"           Evaluation of oligomenorrhea in adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17529\">",
"           Management of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27685\">",
"           Physiology of the normal menstrual cycle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/25/31125\">",
"           Primary dysmenorrhea in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9866\">",
"           Adolescent sexuality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42201\">",
"           Contraception: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/11/12473\">",
"           Diagnosis and management of congenital anomalies of the vagina",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycystic ovary syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39130\">",
"           Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/9/34970\">",
"           Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24297\">",
"           Treatment of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Puberty and adrenarche",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/5/19546\">",
"           Definition, etiology, and evaluation of precocious puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22424\">",
"           Diagnosis and treatment of delayed puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23302\">",
"           Normal adrenarche",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/25/1434\">",
"           Normal puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21481\">",
"           Premature adrenarche",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/49/4889\">",
"           Treatment of precocious puberty",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tuboovarian disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23690\">",
"           Ovarian and fallopian tube torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21033\">",
"           Ovarian cysts and neoplasms in infants, children, and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-810DB086B7-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f14_47_15102=[""].join("\n");
var outline_f14_47_15102=null;
var title_f14_47_15103="Bruising in Cushings disease";
var content_f14_47_15103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Easy bruisability in Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Forearm of a 42-year-old man with Cushing's disease showing multiple ecchymoses due to minimal trauma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David N Orth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_47_15103=[""].join("\n");
var outline_f14_47_15103=null;
